Leerink Partnrs Weighs in on STOK Q1 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings of ($0.49) per share for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.79) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at $0.55 EPS.

A number of other analysts have also recently weighed in on STOK. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Stock Up 0.8 %

Shares of NASDAQ STOK opened at $8.33 on Friday. Stoke Therapeutics has a 52-week low of $5.80 and a 52-week high of $17.58. The firm has a fifty day moving average of $9.49 and a 200-day moving average of $11.49. The stock has a market capitalization of $441.22 million, a PE ratio of -3.97 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million.

Insider Buying and Selling at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock valued at $143,332 in the last ninety days. Insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS acquired a new stake in shares of Stoke Therapeutics in the 4th quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new stake in shares of Stoke Therapeutics in the 4th quarter valued at about $113,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Stoke Therapeutics in the 4th quarter valued at about $124,000. Tower Research Capital LLC TRC raised its stake in shares of Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in shares of Stoke Therapeutics in the 4th quarter valued at about $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.